Regkirona (regdanvimab) Market Report 2026

Regkirona (regdanvimab) Market Overview

• The Regkirona (regdanvimab) market growth in the historic period has been driven by emergency authorization of covid-19 antibody therapies, rapid scale-up of biologic production • Market expansion is supported by ongoing demand for antiviral preparedness, expansion of monoclonal antibody platforms • Growth Driver: Rising Awareness Of Personalized Medicine Driving Market Growth • Market Trend: Inhalation-Based Antibody Delivery Enhances Therapeutic Efficiency • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Regkirona (regdanvimab) Market?

Regkirona refers to regdanvimab, a monoclonal antibody treatment for COVID-19 used to prevent the progression of mild to moderate symptoms in high-risk patients. It works by binding to the spike protein of SARS-CoV-2, blocking the virus from entering human cells and inhibiting replication. The main types of clinical indications in regkirona (regdanvimab) are mild-to-moderate covid-19, severe covid-19, prevention of covid-19 progression, and post-exposure prophylaxis. Mild-to-moderate COVID-19 refers to cases with symptoms such as fever, cough, and fatigue that are manageable at home, with moderate cases involving some shortness of breath but not requiring intensive medical care. It is distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies, catering to various end users such as pediatric, adult, and geriatric.

What Is The Regkirona (regdanvimab) Market Growth Forecast?

The growth in the forecast period can be attributed to ongoing demand for antiviral preparedness, expansion of monoclonal antibody platforms, increasing focus on immunocompromised patient protection, rising investments in pandemic response infrastructure, development of next-generation antiviral antibodies. Major trends in the forecast period include increasing use of monoclonal antibodies in infectious diseases, rising focus on early covid-19 intervention, growing integration with hospital treatment protocols, expansion of pandemic preparedness therapeutics, enhanced emphasis on high-risk patient protection.

Global Regkirona (regdanvimab) Market Segmentation

1) By Clinical Indication: Mild-To-Moderate COVID-19, Severe COVID-19, Prevention Of COVID-19 Progression, Post-Exposure Prophylaxis 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End User: Pediatric, Adult, Geriatric

What Are The Drivers Of The Regkirona (regdanvimab) Market?

The rising awareness of personalized medicine is expected to propel growth of the regkirona (regdanvimab) market going forward. Personalized medicine is a tailored approach to healthcare that customizes treatment plans based on an individual's genetic, environmental, and lifestyle factors to improve treatment effectiveness and minimize side effects. The growing awareness of personalized medicine is fueled by advancements in genomics, better diagnostic technologies, increased public and healthcare sector support, and the rising demand for tailored treatments that improve patient outcomes. Regkirona helps in personalized medicine by providing a targeted treatment for COVID-19 based on specific patient characteristics, such as severity and risk factors. For instance, in February 2024, the Personalized Medicine Coalition, a US-based organization, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from the six approvals in 2022. Therefore, the rising awareness of personalized medicine is due to the growth of the regkirona (regdanvimab) industry. Increased focus on therapeutics for immunocompromised patients is expected to propel the growth of the Regkirona (regdanvimab) market going forward. Therapeutics for immunocompromised patients are treatments that provide direct clinical protection to people with weakened immune systems. Focus on therapeutics for immunocompromised patients is rising because the measurable share of the global population living with clinically significant immune suppression continues to increase, which expands the number of patients who require direct-acting therapeutic protection when vaccines provide limited benefit. Regkirona (regdanvimab) supports the rising focus on therapeutics for immunocompromised patients by providing rapid, passive antibody-based protection that reduces their reliance on endogenous immune responses, which often remain inadequate despite vaccination. For instance, in December 2024, according to the CDC, a US-based public health agency, approximately 6% of U.S. adults have an immunocompromising condition, while 16% of COVID-19 hospitalizations during July 2023–May 2024 occurred among immunocompromised persons. Therefore, heightened demand among a growing, high-risk cohort should drive Regkirona uptake and market growth.

Key Players In The Global Regkirona (regdanvimab) Market

Major companies operating in the regkirona (regdanvimab) market are Celltrion Inc.

Global Regkirona (regdanvimab) Market Trends and Insights

Major companies operating in the Regkirona (regdanvimab) market are focusing on technological advancements, such as inhalation based antibody delivery, to gain a competitive advantage. Inhalation based antibody delivery refers to the administration of monoclonal antibodies via aerosol or nebulizer, allowing direct deposition into the respiratory tract rather than systemic infusion. For instance, in March 2024, the US based biopharma company Inhalon Biopharma launched IN 006, a nebulized formulation of regdanvimab, which in a Phase 1b trial achieved uniform distribution across the lungs and yielded antibody concentrations in the respiratory tract that were up to 20 fold higher than intravenously delivered regdanvimab, while requiring a 90% lower systemic dose. This method promises higher local potency and reduced systemic exposure, though it may pose challenges around manufacturing complexity and stability.

Regional Insights

North America was the largest region in the regkirona (regdanvimab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Regkirona (regdanvimab) Market?

The regkirona (regdanvimab) market consists of sales of products including injections, dosage vials, pre-filled syringes, emergency use authorization kits, and co-packaged products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Regkirona (regdanvimab) Market Report 2026?

The regkirona (regdanvimab) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the regkirona (regdanvimab) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.